-
Netflix to buy Warner Bros. Discovery in deal of the decade
-
French stars Moefana and Atonio return for Champions Cup
-
Penguins queue in Paris zoo for their bird flu jabs
-
Netflix to buy Warner Bros. Discovery for nearly $83 billion
-
Sri Lanka issues fresh landslide warnings as toll nears 500
-
Root says England still 'well and truly' in second Ashes Test
-
Chelsea's Maresca says rotation unavoidable
-
Italian president urges Olympic truce at Milan-Cortina torch ceremony
-
Norris edges Verstappen in opening practice for season-ending Abu Dhabi GP
-
Australia race clear of England to seize control of second Ashes Test
-
Stocks, dollar rise before key US inflation data
-
Trump strategy shifts from global role and vows 'resistance' in Europe
-
Turkey orders arrest of 29 footballers in betting scandal
-
EU hits X with 120-mn-euro fine, risking Trump ire
-
Arsenal's Merino has earned striking role: Arteta
-
Putin offers India 'uninterrupted' oil in summit talks with Modi
-
New Trump strategy vows shift from global role to regional
-
World Athletics ditches long jump take-off zone reform
-
French town offers 1,000-euro birth bonuses to save local clinic
-
After wins abroad, Syria leader must gain trust at home
-
Slot spots 'positive' signs at struggling Liverpool
-
Eyes of football world on 2026 World Cup draw with Trump centre stage
-
South Africa rugby coach Erasmus extends contract until 2031
-
Ex-Manchester Utd star Lingard announces South Korea exit
-
Australia edge ominously within 106 runs of England in second Ashes Test
-
Markets rise ahead of US data, expected Fed rate cut
-
McIlroy survives as Min Woo Lee surges into Australian Open hunt
-
German factory orders rise more than expected
-
India's Modi and Russia's Putin talk defence, trade and Ukraine
-
Flooding kills two as Vietnam hit by dozens of landslides
-
Italy to open Europe's first marine sanctuary for dolphins
-
Hong Kong university suspends student union after calls for fire justice
-
Asian markets rise ahead of US data, expected Fed rate cut
-
Nigerian nightlife finds a new extravagance: cabaret
-
Tanzania tourism suffers after election killings
-
Yo-de-lay-UNESCO? Swiss hope for yodel heritage listing
-
Weatherald fires up as Australia race to 130-1 in second Ashes Test
-
Georgia's street dogs stir affection, fear, national debate
-
Survivors pick up pieces in flood-hit Indonesia as more rain predicted
-
Gibbs runs for three TDs as Lions down Cowboys to boost NFL playoff bid
-
Pandas and ping-pong: Macron ending China visit on lighter note
-
TikTok to comply with 'upsetting' Australian under-16 ban
-
Hope's resistance keeps West Indies alive in New Zealand Test
-
Pentagon endorses Australia submarine pact
-
India rolls out red carpet for Russia's Putin
-
Softbank's Son says super AI could make humans like fish, win Nobel Prize
-
LeBron scoring streak ends as Hachimura, Reaves lift Lakers
-
England all out for 334 in second Ashes Test
-
Hong Kong university axes student union after calls for fire justice
-
'Annoying' Raphinha pulling Barca towards their best
Appetite-regulating hormones in focus as first Nobel Prizes fall
Research into hormones that regulate appetite is seen leading the race for the Nobel Prize in Medicine, to be awarded Monday -- the first in this year's Nobel season.
At a time when more than one billion people suffer from obesity, research into the hormone called "glucagon-like peptide 1" (GLP-1) could be given the nod for the Nobel Prize in Physiology or Medicine this year, experts said.
A new generation of drugs using GLP-1 agonists -- including blockbuster brands Ozempic, Wegovy and Mounjaro -- has provided a valuable tool to fight obesity and diabetes globally.
"Many are guessing that it (the Nobel Prize in Medicine) will go to the people behind GLP-1," Lars Brostrom, science editor at public broadcaster Sveriges Radio, told AFP.
That could help researchers from major US institutions once again dominate the Nobel Prizes in sciences, which are to be announced this week in Stockholm.
But, even if that happens, US politics is to cast a shadow over them, given budget cuts to science programmes ordered by President Donald Trump's government.
Since January, the US National Institutes of Health (NIH) has terminated 2,100 research grants totalling around $9.5 billion and $2.6 billion in contracts, according to an independent database called Grant Watch.
Such cuts could fuel debate over the growing risk that the United States could lose its edge in scientific research.
"In the post-war period, the US has taken over Germany's role as the world's leading scientific nation," Hans Ellegren, secretary general of the Royal Swedish Academy of Sciences, which awards Nobel Prizes in physics, chemistry, and economics, told AFP.
"When they now start cutting research funding, it threatens the country's position."
- Many contenders -
When it comes to GLP-1, as with many other discoveries, it can be hard to narrow down who exactly deserves to be honoured when many scientists around the world have made significant contributions.
Brostrom said some names often speculated upon are Danish physician Jens Juul Holst, and Joel Habener, a professor of medicine at Harvard, as well as Canadian endocrinologist Daniel Drucker and Yugoslav-born American chemist Svetlana Mojsov.
Despite treatments such as Ozempic being recently introduced, and the Nobel Assembly at the Karolinska Institute more often honouring discoveries that are decades old, "it could also be perfect timing" for GLP-1 recognition "because the discovery itself was made back in the 80s", Brostrom said.
In the same field, research on ghrelin, a hormone that stimulates appetite, could earn a Nobel Prize for two Japanese researchers, Kenji Kangawa and Masayasu Kojima, according to David Pendlebury, who heads research analysis at the firm Clarivate -- which predicts potential Nobel winners based on the number of citations of their work.
Pendlebury said that would also form "a nice bookend to a 1994 discovery" by geneticist Jeffrey Friedman, who discovered another appetite-regulating hormone, leptin, and who has previously been spotlighted by Clarivate.
"We have a combination of very nice discoveries, a hormone for appetite, a hormone that suppresses appetite, and this may also play into a lot of speculation of a prize for the GLP-1," he told AFP.
Clarivate also said the work of German medical professor Andrea Ablasser, American virologist Glen N. Barber, and Chinese-American biochemist Zhijian "James" Chen could be honoured "for elucidating the cGAS-STING pathway, a fundamental mechanism of innate immunity".
It noted that Canadian biologist John E. Dick could also be a contender "for identifying leukaemia stem cells and establishing their relevance in therapy failure".
- 'Invisibility cloak' -
For the Nobel Prize in Physics on Tuesday, experts at Sweden's public radio cited research into metamaterials, which has been buzzed about for several years.
British physicist John B. Pendry has in particular been frequently mentioned for his "invisibility cloak" -- a theoretical method to redirect electromagnetic fields around an object.
The Nobel season continues Wednesday with the prize for chemistry, followed on Thursday by the closely watched literature prize and on Friday the peace prize, which Donald Trump has argued should go to him.
The economics prize wraps up the Nobel season on October 13.
In addition to each honour, the prize includes a diploma, a gold medal, and a check for 11 million Swedish kronor ($1.2 million).
T.Bondarenko--BTB